uracil has been researched along with Cirrhosis, Liver in 63 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "BACKGROUND In the European Union, a tablet with fixed doses of ombitasvir, paritaprevir, and ritonavir combined with dasabuvir is an authorized treatment for patients with chronic hepatitis C virus (HCV) infection." | 8.12 | A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania. ( Bacinschi, X; Gales, L; Haineala, B; Iliescu, L; Mercan, A; Popescu, GC; Rodica, A; Serban, D; Toma, L; Zgura, A, 2022) |
| "Ombitasvir + paritaprevir combined with ritonavir and dasabuvir ± ribavirin is an effective treatment for patients infected with genotype 1 hepatitis C who have coagulation disorders." | 8.12 | Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders. ( Ar, C; Bozcan, S; Canbakan, B; Gültürk, İ; Hatemi, İ; Özdemir, S; Sonsuz, A; Yıldırım, S, 2022) |
| " The study included patients from 16 hepatologic centres involved in the AMBER, investigator-initiated study on treatment of chronic hepatitis C patients within a programme preceding EU registration of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin." | 7.88 | Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study. ( Berak, H; Białkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Janczewska, E; Karpińska, E; Karwowska, K; Nazzal, K; Piekarska, A; Simon, K; Tomasiewicz, K; Tronina, O; Tuchendler, E; Zarębska-Michaluk, D; Łucejko, M, 2018) |
| "Hepatic decompensation is a severe on-treatment adverse event for chronic hepatitis C treated with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD)." | 7.88 | Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. ( Chen, WT; Chen, YC; Hsieh, YC; Huang, CH; Jeng, WJ; Lin, CY; Lin, SM; Sheen, IS; Tai, DI; Teng, W, 2018) |
| "Ombitasvir-paritaprevir-ritonavir-dasabuvir may cause type B lactic acidosis." | 7.85 | Ombitasvir-Paritaprevir-Ritonavir-Dasabuvir (Viekira Pak)-Induced Lactic Acidosis. ( Hiensch, RJ; Oberg, CL; Poor, HD, 2017) |
| "Among 41 patients treated, 35 (85%) patients had genotype 1b HCV infection, 6 (15%) had co-infection with human immunodeficiency virus, 35 (85%) failed previous peginterferon and ribavirin therapy, 25 (61%) had compensated liver cirrhosis, and 3 (7%) had liver transplantation." | 7.85 | Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. ( But, DY; Chan, CK; Chan, HL; Chan, KH; Fung, J; Hui, YT; Lai, CL; Lai, MS; Lam, YS; Lao, WC; Li, C; Lui, GC; Seto, WK; Tsang, OT; Wong, GL; Wong, VW; Yuen, MF, 2017) |
| "We investigated the real-world effectiveness of sofosbuvir, ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) in treatment of different subgroups of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, or 4." | 7.83 | Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. ( Berry, K; Beste, LA; Chang, MF; Green, PK; Ioannou, GN; Lowy, E; Su, F; Tsui, JI, 2016) |
| "We observed a sustained viral response (SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 12 wk, in two cases with compensated liver cirrhosis and fully destroyed early hepatocellular carcinoma (HCC)." | 7.83 | Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. ( Antonov, K; Atanasova, E; Boyanova, Y; Jelev, D; Krastev, Z; Mateva, L; Petkova, T; Tomov, B; Zheleva, N, 2016) |
| "We report a case of complete remission of multiple hepatocellular carcinomas after oral administration of enteric-coated tegafur/uracil." | 7.70 | Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. ( Asakura, H; Ebe, Y; Ichida, T; Ishikawa, T; Ishimoto, Y; Naito, M; Nomoto, M; Usuda, H; Yokoyama, J, 1999) |
| "The clinical guidelines suggest that the dosing of cyclosporine (CsA), during combination therapy with paritaprevir/ritonavir-ombitasvir and dasabuvir (PrOD), would be only one-fifth of the pre-PrOD total daily dose to be administered once daily." | 5.72 | Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis. ( Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH, 2022) |
| " The aim of this study was to compare the efficacy and safety of PrOD-based therapy in hepatitis C genotype 1 patients with and without cirrhosis, and to explore pre-treatment factors predictive of sustained viral response (SVR) and serious adverse events (SAEs) on treatment." | 5.46 | Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study. ( Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A, 2017) |
| "We conducted a nonrandomized clinical trial of 12 or 24 weeks of paritaprevir-ritonavir-ombitasvir plus dasabuvir (PrOD) with or without ribavirin in persons with HCV-1/HIV coinfection suppressed with antiretroviral therapy." | 5.34 | Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation. ( Alston-Smith, BL; Anthony, DD; Balagopal, A; Bhattacharya, D; Cohen, DE; Damjanovska, S; Kowal, CM; Shive, CL; Smeaton, LM; Sulkowski, MS; Wyles, DL, 2020) |
| "To review the data with ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection." | 4.91 | Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. ( Gale, SE; Klibanov, OM; Santevecchi, B, 2015) |
| "A fixed-dose tablet comprising ombitasvir (an NS5A replication complex inhibitor), paritaprevir (an NS3/4A protease inhibitor) and ritonavir (a cytochrome P450 inhibitor) taken in combination with dasabuvir (an NS5B polymerase inhibitor) is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in several countries, including the USA (copackaged as Viekira Pak(™)) and those of the EU (Viekirax(®) and Exviera(®))." | 4.91 | Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection. ( Deeks, ED, 2015) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "Ombitasvir + paritaprevir combined with ritonavir and dasabuvir ± ribavirin is an effective treatment for patients infected with genotype 1 hepatitis C who have coagulation disorders." | 4.12 | Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders. ( Ar, C; Bozcan, S; Canbakan, B; Gültürk, İ; Hatemi, İ; Özdemir, S; Sonsuz, A; Yıldırım, S, 2022) |
| "BACKGROUND In the European Union, a tablet with fixed doses of ombitasvir, paritaprevir, and ritonavir combined with dasabuvir is an authorized treatment for patients with chronic hepatitis C virus (HCV) infection." | 4.12 | A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania. ( Bacinschi, X; Gales, L; Haineala, B; Iliescu, L; Mercan, A; Popescu, GC; Rodica, A; Serban, D; Toma, L; Zgura, A, 2022) |
| "The 12-week regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir (OPrD) has shown high efficacy and tolerability in clinical trials for the treatment of chronic hepatitis C virus (HCV)." | 4.02 | Effectiveness of 8- and 12-Week Treatment with Ombitasvir/ Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve HCV Patients in a Real-Life Setting in Romania: the AMETHYST Study. ( Baroiu, L; Cijevschi, C; Diculescu, M; Gheorghe, L; Iliescu, L; Luca, MC; Miftode, E; Mihai, C; Pojoga, C; Sparchez, ZA; Sporea, I; Stanciu, C; Streinu-Cercel, A; Trifan, A, 2021) |
| "Since 2017 treatment-naïve patients infected with genotype 1b of hepatitis C virus and minimal or moderate fibrosis can be treated with Ombitasvir/Paritaprevir/ritonavir + Dasabuvir (OPrD) for 8 weeks according to updated Summary of Product Characteristics." | 3.96 | Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. ( Baka-Ćwierz, B; Belica-Wdowik, T; Białkowska, J; Buczyńska, I; Citko, J; Czauż-Andrzejuk, A; Deroń, Z; Dobracka, B; Dybowska, D; Flisiak, R; Garlicki, A; Halota, W; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Krygier, R; Laurans, Ł; Lorenc, B; Mazur, W; Pabjan, P; Pawłowska, M; Piekarska, A; Simon, K; Sitko, M; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Zarębska-Michaluk, D, 2020) |
| "Hepatic decompensation is a severe on-treatment adverse event for chronic hepatitis C treated with paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD)." | 3.88 | Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis. ( Chen, WT; Chen, YC; Hsieh, YC; Huang, CH; Jeng, WJ; Lin, CY; Lin, SM; Sheen, IS; Tai, DI; Teng, W, 2018) |
| " The study included patients from 16 hepatologic centres involved in the AMBER, investigator-initiated study on treatment of chronic hepatitis C patients within a programme preceding EU registration of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin." | 3.88 | Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study. ( Berak, H; Białkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Janczewska, E; Karpińska, E; Karwowska, K; Nazzal, K; Piekarska, A; Simon, K; Tomasiewicz, K; Tronina, O; Tuchendler, E; Zarębska-Michaluk, D; Łucejko, M, 2018) |
| "Ombitasvir-paritaprevir-ritonavir-dasabuvir may cause type B lactic acidosis." | 3.85 | Ombitasvir-Paritaprevir-Ritonavir-Dasabuvir (Viekira Pak)-Induced Lactic Acidosis. ( Hiensch, RJ; Oberg, CL; Poor, HD, 2017) |
| "Among 41 patients treated, 35 (85%) patients had genotype 1b HCV infection, 6 (15%) had co-infection with human immunodeficiency virus, 35 (85%) failed previous peginterferon and ribavirin therapy, 25 (61%) had compensated liver cirrhosis, and 3 (7%) had liver transplantation." | 3.85 | Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. ( But, DY; Chan, CK; Chan, HL; Chan, KH; Fung, J; Hui, YT; Lai, CL; Lai, MS; Lam, YS; Lao, WC; Li, C; Lui, GC; Seto, WK; Tsang, OT; Wong, GL; Wong, VW; Yuen, MF, 2017) |
| "We observed a sustained viral response (SVR) of ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin therapy, for 12 wk, in two cases with compensated liver cirrhosis and fully destroyed early hepatocellular carcinoma (HCC)." | 3.83 | Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. ( Antonov, K; Atanasova, E; Boyanova, Y; Jelev, D; Krastev, Z; Mateva, L; Petkova, T; Tomov, B; Zheleva, N, 2016) |
| "We investigated the real-world effectiveness of sofosbuvir, ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) in treatment of different subgroups of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, or 4." | 3.83 | Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. ( Berry, K; Beste, LA; Chang, MF; Green, PK; Ioannou, GN; Lowy, E; Su, F; Tsui, JI, 2016) |
| "A 40-year-old man, diagnosed with decompensated liver cirrhosis because of hepatitis C virus, was on the wait list for a liver transplant when he began treatment with the direct-acting antivirals simeprevir 150 mg and sofosbuvir 400 mg." | 3.83 | First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List. ( Ashimkhanova, A; Kaliaskarova, K; Yesmembetov, K, 2016) |
| "We report a case of complete remission of multiple hepatocellular carcinomas after oral administration of enteric-coated tegafur/uracil." | 3.70 | Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil. ( Asakura, H; Ebe, Y; Ichida, T; Ishikawa, T; Ishimoto, Y; Naito, M; Nomoto, M; Usuda, H; Yokoyama, J, 1999) |
| "UFT was administered preoperatively in 20 cases of primary hepatocellular carcinoma, and tegafur, 5-fluorouracil (5-FU), uracil, total thymidylate synthase (TS) and free TS in blood and liver tissue were determined." | 3.67 | [Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis]. ( Ito, Y; Matsuoka, S; Misawa, K; Nagafuchi, E; Nakajima, Y; Ogasawara, K; Sato, N; Uchino, J; Une, Y, 1989) |
| " Overall there was a low rate of serious adverse events (n = 6, 2." | 2.87 | Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis. ( Affonso-de-Araújo, ES; Álvares-da-Silva, MR; Alves, K; Brandão-Mello, CE; Cheinquer, H; Coelho, HS; Cohen, DE; Ferraz, ML; Ferreira, PRA; Furtado, J; Lari, SA; Liu, L; Martinelli, A; Mendes-Correa, MC; Nunes, EP; Parana, R; Pessoa, MG; Pilot-Matias, T; Ramalho-Madruga, JV; Shulman, NS; Silva, G; Tripathi, R, 2018) |
| " Adverse events occurred in 151 (72." | 2.82 | Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. ( Berak, H; Bialkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Halota, W; Horban, A; Jabłkowski, M; Janczewska, E; Jaroszewicz, J; Karpińska, E; Karwowska, K; Knysz, B; Kryczka, W; Lucejko, M; Madej, G; Mozer-Lisewska, I; Nazzal, K; Piekarska, A; Pisula, A; Rostkowska, K; Simon, K; Tomasiewicz, K; Tronina, O; Tudrujek, M; Wawrzynowicz-Syczewska, M; Wiercińska-Drapało, A; Zarębska-Michaluk, D, 2016) |
| "Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent, dynamic disease that occurs across the age spectrum and can lead to cirrhosis and hepatocellular carcinoma." | 2.72 | Evolving Role for Pharmacotherapy in NAFLD/NASH. ( Attia, SL; Mouzaki, M; Softic, S, 2021) |
| " The number and percentage of patients with treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs consistent with hepatic decompensation were reported." | 2.55 | Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. ( Cohen, DE; Cohen, E; Feld, JJ; Foster, GR; Fried, MW; Larsen, L; Mobashery, N; Nelson, DR; Poordad, F; Tatsch, F; Wedemeyer, H, 2017) |
| "02), while it increased the risk of serious adverse events (p = 0." | 2.55 | Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis. ( Abdel-Daim, MM; Abushouk, AI; Ahmed, H; Loutfy, SA; Menshawy, A; Mohamed, A; Negida, A, 2017) |
| "The clinical guidelines suggest that the dosing of cyclosporine (CsA), during combination therapy with paritaprevir/ritonavir-ombitasvir and dasabuvir (PrOD), would be only one-fifth of the pre-PrOD total daily dose to be administered once daily." | 1.72 | Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis. ( Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH, 2022) |
| "The understanding of the pathogenesis of liver fibrosis has grown considerably, but the effective treatments are still lacking." | 1.51 | Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell. ( Cui, S; Field, RA; Li, J; Sun, D; Wang, G; Zang, Y; Zhang, H, 2019) |
| " RBV was dosed by physician discretion between 200 mg weekly and 200 mg daily." | 1.48 | High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease. ( Afghani, AA; Alghamdi, AS; Alghamdi, MN; AlMousa, A; Alswat, K; AlZanbagi, A; Aseeri, M; Assiri, AM; Babatin, MA; Sanai, FM, 2018) |
| "Patients who suffered any adverse event (AE) were 74/240 (30." | 1.48 | Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. ( Aghemo, A; Ascione, A; Bruno, S; Craxì, A; De Luca, M; Fontanella, L; Gasbarrini, A; Giannini, EG; Izzi, A; Marzioni, M; Melazzini, M; Messina, V; Montilla, S; Orlandini, A; Petta, S; Puoti, M; Sangiovanni, V; Trotta, MP; Villa, E; Zignego, AL, 2018) |
| " Adverse events were recorded in 78." | 1.48 | Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study. ( Chamorro-de-Vega, E; De Lorenzo-Pinto, A; Escudero-Vilaplana, V; Gimenez-Manzorro, A; Herranz-Alonso, A; Iglesias-Peinado, I; Rodriguez-Gonzalez, CG; Sanjurjo Saez, M, 2018) |
| " The aim of this study was to compare the efficacy and safety of PrOD-based therapy in hepatitis C genotype 1 patients with and without cirrhosis, and to explore pre-treatment factors predictive of sustained viral response (SVR) and serious adverse events (SAEs) on treatment." | 1.46 | Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study. ( Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A, 2017) |
| " Direct-acting antiviral (DAA) drug regimens are safe and highly effective, allowing administration of treatment also in elderly." | 1.46 | Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. ( Bataga, S; Brisc, C; Caruntu, FA; Chiriac, S; Cijevschi Prelipcean, C; Curescu, M; Gheorghe, L; Girleanu, I; Goldis, A; Iacob, S; Miftode, E; Mihai, C; Preda, C; Rogoveanu, I; Singeap, AM; Sporea, I; Stanciu, C; Stefanescu, G; Trifan, A, 2017) |
| "At the age of 46, he was diagnosed with hepatocellular carcinoma with subsequent resection of the tumour in May 2015." | 1.46 | Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation. ( Rostkowska, K; Simon, K; Szymanek-Pasternak, A, 2017) |
| "Tegafur-uracil has been reported to have only minor adverse effects and is associated with liver injury in 1." | 1.46 | Tegafur-uracil-induced rapid development of advanced hepatic fibrosis. ( Fujiya, M; Hasebe, T; Honda, S; Nakajima, S; Okumura, T; Sawada, K, 2017) |
| "Hepatic decompensation and acute liver failure are rare but severe complications of Ritonavir-boosted Paritaprevir, Ombitasvir and Dasabuvir plus Ribavirin therapy in patients with compensated cirrhosis." | 1.43 | A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis. ( Andreone, P; Magalotti, D; Martino, E; Masetti, M; Scuteri, A; Zoli, M, 2016) |
| "A 77-year-old male with liver cirrhosis was admitted to our hospital for further examination and treatment of liver tumor." | 1.29 | [A case of hepatocellular carcinoma responding to oral administration of UFT]. ( Matsumoto, K; Onodera, H; Otawa, K; Sato, T; Ukai, K, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.76) | 18.7374 |
| 1990's | 2 (3.17) | 18.2507 |
| 2000's | 1 (1.59) | 29.6817 |
| 2010's | 47 (74.60) | 24.3611 |
| 2020's | 10 (15.87) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, YY | 1 |
| Huang, YH | 1 |
| Wu, TH | 1 |
| Loong, CC | 1 |
| Hsu, CC | 1 |
| Chou, YC | 1 |
| Chang, YL | 1 |
| Sonsuz, A | 1 |
| Bozcan, S | 1 |
| Hatemi, İ | 1 |
| Özdemir, S | 1 |
| Canbakan, B | 1 |
| Yıldırım, S | 1 |
| Gültürk, İ | 1 |
| Ar, C | 1 |
| Bacinschi, X | 1 |
| Popescu, GC | 1 |
| Zgura, A | 1 |
| Gales, L | 1 |
| Rodica, A | 1 |
| Mercan, A | 1 |
| Serban, D | 1 |
| Haineala, B | 1 |
| Toma, L | 1 |
| Iliescu, L | 2 |
| Wiegand, J | 1 |
| Buggisch, P | 2 |
| Mauss, S | 2 |
| Boeker, KHW | 1 |
| Klinker, H | 1 |
| Müller, T | 1 |
| Günther, R | 1 |
| Serfert, Y | 1 |
| Manns, MP | 1 |
| Zeuzem, S | 1 |
| Berg, T | 2 |
| Hinrichsen, H | 2 |
| C-Registry, GH | 1 |
| Harrison, SA | 2 |
| Bashir, MR | 1 |
| Guy, CD | 1 |
| Zhou, R | 1 |
| Moylan, CA | 1 |
| Frias, JP | 1 |
| Alkhouri, N | 1 |
| Bansal, MB | 1 |
| Baum, S | 1 |
| Neuschwander-Tetri, BA | 1 |
| Taub, R | 1 |
| Moussa, SE | 1 |
| Zarębska-Michaluk, D | 3 |
| Piekarska, A | 3 |
| Jaroszewicz, J | 2 |
| Klapaczyński, J | 1 |
| Mazur, W | 1 |
| Krygier, R | 1 |
| Belica-Wdowik, T | 1 |
| Baka-Ćwierz, B | 1 |
| Janczewska, E | 3 |
| Pabjan, P | 1 |
| Dobracka, B | 1 |
| Lorenc, B | 1 |
| Tudrujek-Zdunek, M | 1 |
| Tomasiewicz, K | 3 |
| Sitko, M | 1 |
| Garlicki, A | 3 |
| Czauż-Andrzejuk, A | 1 |
| Citko, J | 1 |
| Dybowska, D | 1 |
| Halota, W | 2 |
| Pawłowska, M | 1 |
| Laurans, Ł | 1 |
| Deroń, Z | 1 |
| Buczyńska, I | 1 |
| Simon, K | 4 |
| Białkowska, J | 2 |
| Tronina, O | 3 |
| Flisiak, R | 3 |
| Anthony, DD | 1 |
| Sulkowski, MS | 1 |
| Smeaton, LM | 1 |
| Damjanovska, S | 1 |
| Shive, CL | 1 |
| Kowal, CM | 1 |
| Cohen, DE | 3 |
| Bhattacharya, D | 1 |
| Alston-Smith, BL | 1 |
| Balagopal, A | 1 |
| Wyles, DL | 1 |
| Attia, SL | 1 |
| Softic, S | 1 |
| Mouzaki, M | 1 |
| Fedorchenko, SV | 1 |
| Martynovych, T | 1 |
| Klimenko, Z | 1 |
| Solianyk, I | 1 |
| Trifan, A | 3 |
| Stanciu, C | 3 |
| Sporea, I | 3 |
| Baroiu, L | 1 |
| Diculescu, M | 2 |
| Luca, MC | 1 |
| Miftode, E | 2 |
| Cijevschi, C | 2 |
| Mihai, C | 2 |
| Sparchez, ZA | 1 |
| Pojoga, C | 1 |
| Streinu-Cercel, A | 1 |
| Gheorghe, L | 4 |
| Younossi, ZM | 1 |
| Stepanova, M | 1 |
| Taub, RA | 1 |
| Barbone, JM | 1 |
| Welzel, TM | 1 |
| Sarrazin, C | 1 |
| Baumgarten, A | 1 |
| Christensen, S | 1 |
| Teuber, G | 1 |
| Stein, K | 1 |
| Deterding, K | 1 |
| van Bömmel, F | 1 |
| Heyne, R | 1 |
| John, C | 1 |
| Zimmermann, T | 1 |
| Lutz, T | 1 |
| Schott, E | 1 |
| Hettinger, J | 1 |
| Kleine, H | 1 |
| König, B | 1 |
| Hüppe, D | 1 |
| Wedemeyer, H | 3 |
| Lubel, J | 1 |
| Strasser, S | 1 |
| Stuart, KA | 1 |
| Dore, G | 1 |
| Thompson, A | 1 |
| Pianko, S | 1 |
| Bollipo, S | 1 |
| Mitchell, JL | 1 |
| Fragomeli, V | 1 |
| Jones, T | 1 |
| Chivers, S | 1 |
| Gow, P | 1 |
| Iser, D | 1 |
| Levy, M | 1 |
| Tse, E | 1 |
| Gazzola, A | 1 |
| Cheng, W | 1 |
| Nazareth, S | 1 |
| Galhenage, S | 1 |
| Wade, A | 1 |
| Weltman, M | 1 |
| Wigg, A | 1 |
| MacQuillan, G | 1 |
| Sasadeusz, J | 1 |
| George, J | 1 |
| Zekry, A | 1 |
| Roberts, SK | 1 |
| Petta, S | 2 |
| Marzioni, M | 2 |
| Russo, P | 1 |
| Aghemo, A | 2 |
| Alberti, A | 1 |
| Ascione, A | 2 |
| Antinori, A | 1 |
| Bruno, R | 1 |
| Bruno, S | 2 |
| Chirianni, A | 1 |
| Gaeta, GB | 1 |
| Giannini, EG | 2 |
| Merli, M | 1 |
| Messina, V | 2 |
| Montilla, S | 2 |
| Perno, CF | 1 |
| Puoti, M | 2 |
| Raimondo, G | 1 |
| Rendina, M | 1 |
| Silberstein, FC | 1 |
| Villa, E | 2 |
| Zignego, AL | 2 |
| Pani, L | 1 |
| Craxì, A | 2 |
| Poordad, F | 3 |
| Nelson, DR | 1 |
| Feld, JJ | 2 |
| Fried, MW | 2 |
| Larsen, L | 2 |
| Cohen, E | 1 |
| Mobashery, N | 1 |
| Tatsch, F | 1 |
| Foster, GR | 1 |
| Yu, ML | 1 |
| Chen, YL | 1 |
| Huang, CF | 1 |
| Lin, KH | 1 |
| Yeh, ML | 1 |
| Huang, CI | 1 |
| Hsieh, MH | 1 |
| Lin, ZY | 1 |
| Chen, SC | 1 |
| Huang, JF | 1 |
| Dai, CY | 1 |
| Chuang, WL | 1 |
| Leventer-Roberts, M | 1 |
| Hammerman, A | 1 |
| Brufman, I | 1 |
| Hoshen, M | 1 |
| Braun, M | 1 |
| Ashur, Y | 1 |
| Lieberman, N | 1 |
| Balicer, R | 1 |
| Ahmed, H | 1 |
| Abushouk, AI | 1 |
| Menshawy, A | 1 |
| Mohamed, A | 1 |
| Negida, A | 1 |
| Loutfy, SA | 1 |
| Abdel-Daim, MM | 1 |
| Honda, S | 1 |
| Sawada, K | 1 |
| Hasebe, T | 1 |
| Nakajima, S | 1 |
| Fujiya, M | 1 |
| Okumura, T | 1 |
| Szymanek-Pasternak, A | 1 |
| Rostkowska, K | 2 |
| Iacob, S | 3 |
| Curescu, M | 2 |
| Brisc, C | 2 |
| Caruntu, F | 1 |
| Simionov, I | 1 |
| Gheorghe, C | 2 |
| Iacob, R | 2 |
| Arama, V | 1 |
| Sirli, R | 1 |
| Sanai, FM | 1 |
| Alghamdi, AS | 1 |
| Afghani, AA | 1 |
| Alswat, K | 1 |
| AlZanbagi, A | 1 |
| Alghamdi, MN | 1 |
| AlMousa, A | 1 |
| Aseeri, M | 1 |
| Assiri, AM | 1 |
| Babatin, MA | 1 |
| Chamorro-de-Vega, E | 1 |
| Gimenez-Manzorro, A | 1 |
| Rodriguez-Gonzalez, CG | 1 |
| Escudero-Vilaplana, V | 1 |
| De Lorenzo-Pinto, A | 1 |
| Iglesias-Peinado, I | 1 |
| Herranz-Alonso, A | 1 |
| Sanjurjo Saez, M | 1 |
| Cijevschi Prelipcean, C | 1 |
| Stefanescu, G | 1 |
| Girleanu, I | 1 |
| Chiriac, S | 1 |
| Goldis, A | 1 |
| Bataga, S | 1 |
| Rogoveanu, I | 1 |
| Preda, C | 1 |
| Caruntu, FA | 1 |
| Singeap, AM | 1 |
| Amano, Y | 1 |
| Tsuchiya, S | 1 |
| Imai, M | 1 |
| Tohyama, K | 1 |
| Matsukawa, J | 1 |
| Isono, O | 1 |
| Yasuno, H | 1 |
| Enya, K | 1 |
| Koumura, E | 1 |
| Nagabukuro, H | 1 |
| Isakov, V | 1 |
| Paduta, D | 1 |
| Viani, RM | 1 |
| Enejosa, JV | 1 |
| Pasechnikov, V | 1 |
| Znoyko, O | 1 |
| Ogurtsov, P | 1 |
| Bogomolov, PO | 1 |
| Maevskaya, MV | 1 |
| Chen, X | 1 |
| Shulman, NS | 3 |
| De Luca, M | 1 |
| Melazzini, M | 1 |
| Trotta, MP | 1 |
| Sangiovanni, V | 1 |
| Izzi, A | 1 |
| Orlandini, A | 1 |
| Fontanella, L | 1 |
| Gasbarrini, A | 2 |
| Łucejko, M | 1 |
| Karpińska, E | 2 |
| Nazzal, K | 2 |
| Bolewska, B | 2 |
| Berak, H | 2 |
| Fleischer-Stępniewska, K | 2 |
| Karwowska, K | 2 |
| Tuchendler, E | 1 |
| Cerban, R | 1 |
| Pietrareanu, C | 1 |
| Ester, C | 1 |
| Popescu, I | 1 |
| Hsieh, YC | 1 |
| Jeng, WJ | 1 |
| Huang, CH | 1 |
| Teng, W | 1 |
| Chen, WT | 1 |
| Chen, YC | 1 |
| Lin, SM | 1 |
| Tai, DI | 1 |
| Lin, CY | 2 |
| Sheen, IS | 2 |
| Puigvehí, M | 1 |
| De Cuenca, B | 1 |
| Viu, A | 1 |
| Diago, M | 1 |
| Turnes, J | 1 |
| Gea, F | 1 |
| Pascasio, JM | 1 |
| Lens, S | 1 |
| Cabezas, J | 1 |
| Badia, E | 1 |
| Olveira, A | 1 |
| Morillas, RM | 1 |
| Torras, X | 1 |
| Montoliu, S | 1 |
| Cordero, P | 1 |
| Castro, JL | 1 |
| Salmerón, J | 1 |
| Molina, E | 1 |
| Sánchez-Ruano, JJ | 1 |
| Moreno, J | 1 |
| Antón, MD | 1 |
| Moreno, JM | 1 |
| De la Vega, J | 1 |
| Calleja, JL | 1 |
| Carrión, JA | 1 |
| Pessoa, MG | 1 |
| Ramalho-Madruga, JV | 1 |
| Alves, K | 1 |
| Nunes, EP | 1 |
| Cheinquer, H | 1 |
| Brandão-Mello, CE | 1 |
| Mendes-Correa, MC | 1 |
| Ferraz, ML | 1 |
| Ferreira, PRA | 1 |
| Álvares-da-Silva, MR | 1 |
| Coelho, HS | 1 |
| Affonso-de-Araújo, ES | 1 |
| Furtado, J | 1 |
| Parana, R | 1 |
| Silva, G | 1 |
| Lari, SA | 1 |
| Liu, L | 1 |
| Tripathi, R | 1 |
| Pilot-Matias, T | 1 |
| Martinelli, A | 1 |
| Zhang, H | 1 |
| Sun, D | 1 |
| Wang, G | 1 |
| Cui, S | 1 |
| Field, RA | 1 |
| Li, J | 1 |
| Zang, Y | 1 |
| Lee, YC | 1 |
| Hu, TH | 2 |
| Hung, CH | 2 |
| Lu, SN | 2 |
| Chen, CH | 3 |
| Wang, JH | 1 |
| Lin, CL | 1 |
| Tung, SY | 1 |
| Hsieh, SY | 1 |
| Chien, RN | 1 |
| Preda, CM | 1 |
| Baicus, C | 1 |
| Sandra, I | 1 |
| Oproiu, A | 1 |
| Manuc, T | 1 |
| Constantinescu, I | 1 |
| Gavrila, D | 1 |
| Dumitru, R | 1 |
| Vasilescu, C | 1 |
| Tieranu, C | 1 |
| Istratescu, D | 1 |
| Voiosu, T | 1 |
| Manuc, M | 1 |
| Höner zu Siederdissen, C | 1 |
| Cornberg, M | 1 |
| Gamal, N | 1 |
| Vitale, G | 1 |
| Andreone, P | 2 |
| Klibanov, OM | 1 |
| Gale, SE | 1 |
| Santevecchi, B | 1 |
| Beinhardt, S | 1 |
| Peck-Radosavljevic, M | 2 |
| Hofer, H | 1 |
| Ferenci, P | 3 |
| Colombo, M | 1 |
| Deeks, ED | 1 |
| Bailly, F | 1 |
| Pradat, P | 1 |
| Virlogeux, V | 1 |
| Zoulim, F | 1 |
| Forns, X | 1 |
| Pedrosa, M | 1 |
| Berenguer, M | 1 |
| Shiffman, ML | 1 |
| Lovell, S | 1 |
| Trinh, R | 2 |
| Lopez-Talavera, JC | 1 |
| Everson, G | 1 |
| Moreno, C | 1 |
| Tam, E | 1 |
| Bourgeois, S | 1 |
| Horsmans, Y | 1 |
| Elkhashab, M | 1 |
| Bernstein, DE | 1 |
| Younes, Z | 1 |
| Reindollar, RW | 1 |
| Fu, B | 1 |
| Howieson, K | 1 |
| Polepally, AR | 1 |
| Pangerl, A | 1 |
| Cheng, EY | 1 |
| Saab, S | 2 |
| Holt, CD | 1 |
| Busuttil, RW | 1 |
| Krastev, Z | 1 |
| Jelev, D | 1 |
| Antonov, K | 1 |
| Petkova, T | 1 |
| Atanasova, E | 1 |
| Zheleva, N | 1 |
| Tomov, B | 1 |
| Boyanova, Y | 1 |
| Mateva, L | 1 |
| Ioannou, GN | 1 |
| Beste, LA | 1 |
| Chang, MF | 1 |
| Green, PK | 1 |
| Lowy, E | 1 |
| Tsui, JI | 1 |
| Su, F | 1 |
| Berry, K | 1 |
| Virabhak, S | 1 |
| Parisé, H | 1 |
| Johnson, S | 1 |
| Wang, A | 1 |
| Misurski, D | 1 |
| Gonzalez, YS | 1 |
| Juday, T | 1 |
| Wawrzynowicz-Syczewska, M | 1 |
| Bialkowska, J | 1 |
| Madej, G | 1 |
| Lucejko, M | 1 |
| Pisula, A | 1 |
| Kryczka, W | 1 |
| Wiercińska-Drapało, A | 1 |
| Mozer-Lisewska, I | 1 |
| Jabłkowski, M | 1 |
| Horban, A | 1 |
| Knysz, B | 1 |
| Tudrujek, M | 1 |
| Oberg, CL | 1 |
| Hiensch, RJ | 1 |
| Poor, HD | 1 |
| Yesmembetov, K | 1 |
| Ashimkhanova, A | 1 |
| Kaliaskarova, K | 1 |
| Chan, HL | 1 |
| Tsang, OT | 1 |
| Hui, YT | 1 |
| Fung, J | 1 |
| Lui, GC | 1 |
| Lai, CL | 1 |
| Wong, GL | 1 |
| Chan, KH | 1 |
| But, DY | 1 |
| Lai, MS | 1 |
| Lao, WC | 1 |
| Chan, CK | 1 |
| Lam, YS | 1 |
| Seto, WK | 1 |
| Li, C | 1 |
| Yuen, MF | 1 |
| Wong, VW | 1 |
| Masetti, M | 1 |
| Magalotti, D | 1 |
| Martino, E | 1 |
| Scuteri, A | 1 |
| Zoli, M | 1 |
| Steiner, S | 1 |
| Bucsics, T | 1 |
| Schwabl, P | 1 |
| Mandorfer, M | 1 |
| Scheiner, B | 1 |
| Aichelburg, MC | 1 |
| Grabmeier-Pfistershammer, K | 1 |
| Trauner, M | 1 |
| Reiberger, T | 1 |
| Ponziani, FR | 1 |
| Siciliano, M | 1 |
| Lionetti, R | 1 |
| Pasquazzi, C | 1 |
| Gianserra, L | 1 |
| D'Offizi, G | 1 |
| Pompili, M | 1 |
| Onodera, H | 1 |
| Ukai, K | 1 |
| Matsumoto, K | 1 |
| Otawa, K | 1 |
| Sato, T | 2 |
| Ishikawa, T | 1 |
| Ichida, T | 1 |
| Ishimoto, Y | 1 |
| Yokoyama, J | 1 |
| Nomoto, M | 1 |
| Ebe, Y | 1 |
| Usuda, H | 1 |
| Naito, M | 1 |
| Asakura, H | 1 |
| Aguayo, A | 1 |
| Patt, YZ | 1 |
| Une, Y | 1 |
| Ito, Y | 1 |
| Ogasawara, K | 1 |
| Nagafuchi, E | 1 |
| Matsuoka, S | 1 |
| Misawa, K | 1 |
| Sato, N | 1 |
| Nakajima, Y | 1 |
| Uchino, J | 1 |
| Ikeda, K | 1 |
| Kumada, H | 1 |
| Arase, Y | 1 |
| Chayama, K | 1 |
| Gunji, T | 1 |
| Yoshiba, A | 1 |
| Irimoto, M | 1 |
| Oguma, S | 1 |
| Sakai, K | 1 |
| Sato, R | 1 |
| Ouchi, K | 1 |
| Owada, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection[NCT04369807] | 693 participants (Actual) | Observational | 2020-04-21 | Completed | |||
| A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis[NCT02912260] | Phase 2 | 125 participants (Actual) | Interventional | 2016-09-30 | Active, not recruiting | ||
| A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-effect of Single and Multiple Oral Doses of RJ4287 in Healthy Volunteers[NCT05921006] | Phase 1 | 98 participants (Anticipated) | Interventional | 2023-06-13 | Recruiting | ||
| Improvement of Laboratory Diagnostics in Hypothyroid Patients Using Levothyroxine[NCT06083636] | 500 participants (Anticipated) | Observational | 2022-07-26 | Recruiting | |||
| Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)[NCT02194998] | Phase 2 | 46 participants (Actual) | Interventional | 2015-09-16 | Terminated (stopped due to The study closed to accrual before the planned accrual goal was attained due to the availability of newer directly-acting antiviral (DAA) treatments for HCV.) | ||
| Efficacy and Safety in Clinical Practice of Ombitasvir/Paritaprevir/ Ritonavir and Dasabuvir Administered for 8 Weeks (3D8) in Treatment-naïve Genotype 1b Hepatitis C Virus Infected Patients: Analysis of Data From Hepa-C Registry.[NCT03122132] | 200 participants (Actual) | Observational | 2017-02-20 | Completed | |||
| A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOIS[NCT01704755] | Phase 3 | 381 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-III)[NCT02219503] | Phase 3 | 60 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| An Open Label, Proof of Concept Study to Evaluate the Feasibility and Safety of Kidney Transplant From HCV Positive Donors Into HCV Negative Recipient[NCT03801707] | Phase 2/Phase 3 | 54 participants (Actual) | Interventional | 2019-03-22 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
HIV-1 VF was defined as two consecutive HIV-1 RNA results ≥ 200 copies/mL. (NCT02194998)
Timeframe: From treatment initiation to 4 weeks after last dose of HCV study treatment. HIV-1 RNA was measured at weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 28. The durations for HCV study treatment for Cohorts A/C and Cohorts B/D were 24 and 12 weeks, respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 1 |
HCV VF was defined as follows: confirmed increase from nadir in HCV RNA (defined as two consecutive HCV RNA measurements of >1 log10 IU/mL above nadir) at any time point; failure to achieve HCV RNA
Timeframe: From treatment initiation to either 24 weeks (for Cohort A and C) or 12 weeks (for Cohort B and D). The duration for HCV study treatment for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 1 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 1 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
Participants who had diagnoses leading to premature HCV study treatment or HIV-1 ARV discontinuation post treatment initiation. (NCT02194998)
Timeframe: From treatment initiation to end of study follow-up at 48 weeks.The duration for HCV study treatment for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively. The duration for ARV treatment for all cohorts was 48 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 1 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
"Participants with an observed laboratory abnormalities grade 3 or higher post treatment initiation.~If entry (pre-treatment) lab result was grade 3, then a grade 4 result was required to meet this outcome.~Severity grading was based on DAIDS AE Grading Table, Version 1.0." (NCT02194998)
Timeframe: From treatment initiation to 30 days post date of last dose of HCV study treatment (whether planned or premature discontinuation). The duration for HCV study treatment for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 5 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 3 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 3 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
Participants who experienced at least one observed SAEs as defined by ICH after initiating HCV study treatment through 30 days post date of last dose of HCV study treatment. (NCT02194998)
Timeframe: From treatment initiation to 30 days post date of last dose of HCV study treatment (whether planned or premature discontinuation). The duration for HCV study treatment for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 1 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 1 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 2 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
"Participants with signs/symptoms of grade 3 or higher post treatment initiation.~Participants with grade 3 sign/symptom prior to treatment initiation must have had one grade higher than pre-treatment to meet this outcome.~Severity grading was based on DAIDS AE Grading Table, Version 1.0." (NCT02194998)
Timeframe: From treatment initiation to 30 days post date of last dose of HCV study treatment (whether planned or premature discontinuation). The duration for HCV study treatment for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 2 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 3 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
Participants with one or more genotype mutations in protease conferring major resistance to any HIV-1 Protease Inhibitors (PI) antiretroviral drug, from a plasma sample drawn following confirmed HIV-1 VF outcome. (NCT02194998)
Timeframe: At confirmation of HIV-1 virologic failure.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
"SVR12 was defined as HCV RNA less than the assay LLOQ (<15 IU/mL) at 12 weeks post HCV treatment discontinuation.~A two-sided 90% confidence interval was calculated for the percentage of participants with SVR12 response using Clopper-Pearson method.~For those whose HCV early responses prior to SVR12 evaluation met the guidelines for HCV Virologic Failure (VF), their SVR12 outcome was defined as non-response. Those missing a HCV RNA result from the week 12 post HCV treatment discontinuation visit (and missing all subsequent evaluations) were considered non-responders. However, if HCV RNA evaluations subsequent to week 12 post treatment discontinuation were non-missing, then the first HCV RNA subsequent to week 12 post treatment discontinuation was instead used to define the primary outcome." (NCT02194998)
Timeframe: At 12 weeks after last dose of HCV study treatment. The duration for study treatment for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 95.2 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 60 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 100 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 100 |
"SVR24 was defined as HCV RNA less than the assay LLOQ (<15 IU/mL) at 24 weeks post treatment discontinuation.~A two-sided 90% confidence interval was calculated for the percentage of SVR24 response using method of Clopper-Pearson.~For those whose HCV early responses prior to SVR24 evaluation met the guidelines for HCV VF, their SVR24 outcome was defined as non-response. Those missing a HCV RNA result from the week 24 post HCV treatment discontinuation visit (and missing all subsequent evaluations) were considered non-responders. However, if HCV RNA evaluations subsequent to week 24 post treatment discontinuation were non-missing, then the first HCV RNA subsequent to week 24 post treatment discontinuation was instead used to define the primary outcome." (NCT02194998)
Timeframe: At 24 weeks after the date of last dose of HCV study treatment. The duration for study treatment for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 90.5 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 60 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 93.3 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 100 |
Absolute change from baseline in IP-10 (Interferon gamma-induced protein 10) concentration in plasma, calculated as value at the later time point minus baseline value. Baseline was defined as the date of first treatment dose. (NCT02194998)
Timeframe: At baseline, end of HCV treatment (EOT), and 12 weeks post EOT. The EOT for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | pg/mL (Median) | |
|---|---|---|
| Change from baseline to EOT | Change from baseline to 12 weeks post EOT | |
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | -244.4 | -127 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | -22.2 | -29.1 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | -116 | -83.1 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | -61.1 | -114.9 |
Absolute change from baseline in sCD14 levels in plasma calculated as value at the later time point minus baseline value. Baseline was defined as the date of first treatment dose. (NCT02194998)
Timeframe: At baseline, end of HCV treatment (EOT), and 12 weeks post EOT. The EOT for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | ng/mL (Median) | |
|---|---|---|
| Change from baseline to EOT | Change from baseline to 12 weeks post EOT | |
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 307.6 | 145.2 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | -1,063.2 | -894.2 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | -380.3 | -22.6 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 318.2 | -987.0 |
Levels of IP-10 (Interferon gamma-induced protein 10) concentration in plasma. Baseline was defined as the date of first treatment dose. (NCT02194998)
Timeframe: At baseline, end of HCV treatment (EOT), and 12 weeks post EOT. The EOT for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | pg/mL (Median) | ||
|---|---|---|---|
| IP-10 at baseline | IP-10 at EOT | IP-10 at 12 weeks post EOT | |
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 379 | 100.9 | 94.6 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 120.2 | 60.4 | 85.5 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 225.5 | 76.6 | 82.5 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 196.4 | 182.6 | 159.5 |
Levels of sCD14. Baseline was defined as the date of first treatment dose. (NCT02194998)
Timeframe: At baseline, end of HCV treatment (EOT), and 12 weeks post EOT. The EOT for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | ng/mL (Median) | ||
|---|---|---|---|
| sCD14 at Baseline | sCD14 at EOT | sCD14 at 12 weeks post EOT | |
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 1,832.0 | 2,126.5 | 1,977.3 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 2,226.8 | 1,132.8 | 1,367.4 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 3,157.0 | 2,421.1 | 3,424.5 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 3,092.0 | 2,801.3 | 2,608.3 |
Virologic failure during treatment was defined as rebound (confirmed HCV RNA greater than or equal to the lower limit of quantitation [≥ LLOQ] after HCV RNA < LLOQ during treatment, or confirmed increase from the lowest value post baseline in HCV RNA [2 consecutive HCV RNA measurements > 1 log(subscript)10(subscript) IU/mL above the lowest value post baseline] at any time point during treatment), or fail to suppress (HCV RNA ≥ LLOQ persistently during treatment with at least 6 weeks [≥ 36 days] of treatment). (NCT01704755)
Timeframe: Baseline (Day 1), and Treatment Weeks 1, 2, 4, 6, 8, 10, 12, 16, 20, and 24
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 0.5 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 1.7 |
The percentage of participants with sustained virologic response (plasma Hepatitis C virus ribonucleic acid [HCV RNA] level less than the lower limit of quantitation [< LLOQ]) 12 weeks after the last dose of study drug. (NCT01704755)
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 91.8 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 96.5 |
A sustained virologic response is defined as plasma Hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (< LLOQ) 12 weeks after the last dose of study drug. (NCT01704755)
Timeframe: 12 weeks after the last actual dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 91.8 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 96.5 |
Participants were considered to have virologic relapse after treatment if they had confirmed quantifiable plasma Hepatitis C virus ribonucleic acid (HCV RNA) ≥ lower limit of quantification (LLOQ) between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment with HCV RNA < LLOQ at the end of treatment. (NCT01704755)
Timeframe: within 12 weeks after the last dose of study drug
| Intervention | Percentage of participants (Number) |
|---|---|
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 12 Weeks | 5.9 |
| ABT-450/r/ABT-267 and ABT-333, Plus RBV for 24 Weeks | 0.6 |
On-Treatment Virologic Failure is defined as confirmed HCV RNA >= LLOQ after HCV RNA < LLOQ during treatment, or confirmed increase from nadir (local minimum value) in HCV RNA [2 consecutive HCV RNA measurements > 1 log10 IU/mL above nadir] at any time point during treatment, or failure to suppress during treatment [all on-treatment values of HCV RNA >= LLOQ] with at least 6 weeks [defined as active study drug duration ≥ 36 days] of treatment. (NCT02219503)
Timeframe: Day 1 through Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir | 0 |
Post- Treatment Relapse is defined as confirmed HCV RNA >= LLOQ between end of treatment and 12 weeks after last actual dose of active study drug [up to and including the SVR12 assessment time point] for a participant with HCV RNA < LLOQ at Final Treatment Visit who completes treatment. (NCT02219503)
Timeframe: Post-treatment Day 1 to Post-treatment Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir | 0 |
"Sustained Virologic Response 12 (SVR12) is defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (< LLOQ; < 25 IU/mL) 12 weeks after the last dose of study drug.~The primary efficacy endpoints were non-inferiority and superiority of the percentage of participants who achieved sustained virologic response 12 weeks after treatment in each treatment arm compared with the historical threshold for sofosbuvir and peginterferon (pegIFN)/RBV for the treatment of subjects with HCV GT1b infection and cirrhosis." (NCT02219503)
Timeframe: Post-treatment Day 1 to Post-treatment Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir | 100 |
Proportion of patients with undetectable hepatitis C virus (HCV) polymerase chain reaction (PCR) at 12 weeks after completion of HCV treatment was to test the efficacy of the treatment. (NCT03801707)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Group | 28 |
Estimated glomerular filtration rate (eGFR) at 6 and 12 months post-transplant was to test the safety of utilizing of HepC positive kidneys. (NCT03801707)
Timeframe: 6 and 12 months
| Intervention | ml/min/1.73m^2 (Median) | |
|---|---|---|
| eGFR at 6 months | eGFR at 12 months | |
| Intervention Group | 54 | 46 |
Graft survival at 6 and 12 months measuring safety of utilizing HepC positive kidneys. (NCT03801707)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 6 months graft survival | 12 months graft survival | |
| Intervention Group | 30 | 30 |
Patient's survival at 6 and 12 months measuring safety of utilizing of HepC positive kidneys. (NCT03801707)
Timeframe: 6 and 12 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 6 months patient survival | 12 months patient survival | |
| Intervention Group | 30 | 30 |
11 reviews available for uracil and Cirrhosis, Liver
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Evolving Role for Pharmacotherapy in NAFLD/NASH.
Topics: Adult; Benzhydryl Compounds; Chenodeoxycholic Acid; Child; Clinical Trials, Phase III as Topic; Fibr | 2021 |
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; C | 2017 |
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; G | 2017 |
[All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clini | 2014 |
ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Clinical Trials, | 2015 |
Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase I as Topic; Clinical | 2015 |
Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cholestasis, Intrahepatic; Clinical Trials | 2015 |
Interferon-free therapy for hepatitis C: The hurdles amid a golden era.
Topics: 2-Naphthylamine; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Ch | 2015 |
Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance; Drug Resist | 2015 |
Nonsurgical treatment of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Chemoemboli | 2001 |
9 trials available for uracil and Cirrhosis, Liver
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation.
Topics: 2-Naphthylamine; Adult; Anilides; Anti-HIV Agents; Antiviral Agents; Biomarkers; Carbamates; Coinfec | 2020 |
Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life.
Topics: Adult; Double-Blind Method; Female; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic | 2022 |
Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinatio | 2018 |
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Brazil; Carbamates; Cyclopropanes; Drug Co | 2018 |
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dru | 2015 |
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administra | 2016 |
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administra | 2016 |
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administra | 2016 |
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administra | 2016 |
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Diarrhea; Drug Therap | 2016 |
44 other studies available for uracil and Cirrhosis, Liver
| Article | Year |
|---|---|
Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Interacti | 2022 |
Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Child; Cyclopropanes; Drug Therapy, | 2022 |
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; H | 2022 |
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Car | 2019 |
Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; | 2020 |
Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir and dasabuvir+sofosbuvir+ribavirin in patients with chronic hepatitis C, subtype 1b, and cirrhosis, who failed previous treatment with first- and second-generation NS5A inhibitors.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Co | 2021 |
Effectiveness of 8- and 12-Week Treatment with Ombitasvir/ Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve HCV Patients in a Real-Life Setting in Romania: the AMETHYST Study.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Cyclopropanes; Drug The | 2021 |
Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Com | 2017 |
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Bilirubin; Biomarkers; Carbamates; Cyclopr | 2017 |
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Cycl | 2017 |
Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience.
Topics: 2-Naphthylamine; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; | 2018 |
Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.
Topics: 2-Naphthylamine; Aged; Anilides; Carbamates; Cyclopropanes; Drug Combinations; Female; Genotype; Hep | 2017 |
Tegafur-uracil-induced rapid development of advanced hepatic fibrosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Biopsy; Carcinoma, Hepatocellular; Di | 2017 |
Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; D | 2017 |
Real-Life Use of 3 Direct-Acting Antiviral Regimen in a Large Cohort of Patients with Genotype-1b HCV Compensated Cirrhosis.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combinat | 2017 |
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug | 2018 |
Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug I | 2018 |
Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dru | 2017 |
Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis.
Topics: Animals; Dose-Response Relationship, Drug; Drug Combinations; Hypoglycemic Agents; Liver; Liver Cirr | 2018 |
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Cyclop | 2018 |
Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyc | 2018 |
100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; | 2018 |
Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cy | 2018 |
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropan | 2019 |
Alogliptin alleviates liver fibrosis via suppression of activated hepatic stellate cell.
Topics: Animals; Cell Line; Dipeptidyl-Peptidase IV Inhibitors; Hepatic Stellate Cells; Humans; Liver Cirrho | 2019 |
The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Female; Genotype; Hep | 2019 |
Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combinat | 2019 |
Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Chemoembol | 2019 |
Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy | 2015 |
Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinica | 2015 |
Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropa | 2016 |
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Female | 2016 |
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocel | 2016 |
Ombitasvir-Paritaprevir-Ritonavir-Dasabuvir (Viekira Pak)-Induced Lactic Acidosis.
Topics: 2-Naphthylamine; Acidosis, Lactic; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combi | 2017 |
First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combina | 2016 |
Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Administra | 2017 |
A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis.
Topics: 2-Naphthylamine; Aged, 80 and over; Anilides; Antiviral Agents; Ascites; Carbamates; Chemical and Dr | 2016 |
Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.
Topics: 2-Naphthylamine; Adult; AIDS-Related Opportunistic Infections; Anilides; Anti-HIV Agents; Antiviral | 2017 |
Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; H | 2017 |
[A case of hepatocellular carcinoma responding to oral administration of UFT].
Topics: Administration, Oral; Aged; alpha-Fetoproteins; Biomarkers; Carcinoma, Hepatocellular; Drug Combinat | 1996 |
Complete remission of multiple hepatocellular carcinomas associated with hepatitis C virus-related, decompensated liver cirrhosis by oral administration of enteric-coated tegafur/uracil.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 1999 |
[Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo | 1989 |
[Risk factors for side effects of long-term administration of 5-fluorouracil derivatives in patients with hepatocellular carcinoma associated with liver cirrhosis--relationship with serum concentration of anti-tumor agents and side effect].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Brain Diseases; Carcinoma, Hepatocell | 1988 |
[FT, 5-FU and uracil concentrations of the blood, bile and tissue of hepatoma with liver cirrhosis after oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bile; Carcinoma, Hepatocellula | 1987 |